Gemcitabine for relapsed or resistant lymphoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/11/5/595/19478254/11-5-595.pdf
Reference18 articles.
1. Gemcitabine: Pre-clinical pharmacology and mechanisms of action;Plunkett;Semin Oncol,1996
2. Experimental drugs and drug combinations in pancreatic cancer;Kroep;Ann Oncol,1999
3. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer;Schmid;Anticancer Drugs,1999
4. Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer;Fossella;J Clin Oncol,1997
5. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer;Kelly;Ann Oncol,1999
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group;Annals of Hematology;2024-03-09
2. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial;British Journal of Haematology;2022-04
3. Physicochemical and in vitro cytotoxicity studies of inclusion complex between gemcitabine and cucurbit[7]uril host;Bioorganic Chemistry;2020-06
4. Revolutionizing technologies of nanomicelles for combinatorial anticancer drug delivery;Archives of Pharmacal Research;2020-01
5. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas;Anti-Cancer Drugs;2017-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3